This year it could be at least 11 future blockbusters, according to EvaluatePharma data, a healthy haul that helps explain ongoing investor support for the sector.
The cholesterol-lowering anti-PCSK9s from Sanofi and Amgen, a heart failure pill from Novartis and Vertex’s follow-on cystic fibrosis therapy represent the class of 2015’s biggest hopes. However several other novel products are attracting substantial commercial expectations, raising the pressure on the likes of GlaxoSmithKline, AbbVie and Synageva to deliver (see tables).
The analysis is based on consensus forecasts from equity analysts, and extracts the top 10 biotechnology and small-molecule drugs likely to reach the market this year.
Some are more likely to make it than others, of course, and Novartis’s novel psoriasis treatment Cosentyx looks unlikely to disappoint – it received European backing earlier this week, and a US decision is due by the end of the month; an FDA panel already gave it unanimous backing.
Dead certs include AstraZeneca’s PARP inhibitor, which won both US and European backing at the very end of 2014, and Merck’s newly acquired Zerbaxa, which won approval shortly after the Cubist acquisition in December. (Más)